<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148131">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090387</url>
  </required_header>
  <id_info>
    <org_study_id>BL20</org_study_id>
    <nct_id>NCT02090387</nct_id>
  </id_info>
  <brief_title>Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.</brief_title>
  <official_title>Evaluation of a Complete Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects During Bed Rest and Recovery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effects of oral nutritional supplements (ONS) on attenuating the
      lean body mass (LBM) loss that occurs after bed rest.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Total lean body mass</measure>
    <time_frame>Baseline to Study Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hand-grip strength</measure>
    <time_frame>Baseline, Study Day 10, Study Week 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Battery (SPPB)</measure>
    <time_frame>Baseline, Study Day 10, Study Week 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isokinetic leg strength</measure>
    <time_frame>Baseline, Study Day 10 and Study Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Screening Visits 1 and 3; Baseline; Study Days 2, 4, 6, 8 and 10; Study Weeks 3, 6, 9 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculated BMI = weight/height2 (kg/m2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower extremity lean mass</measure>
    <time_frame>Baseline, Study Day 10, Study Weeks 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by DXA; Change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control ONS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ONS without AN777</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational ONS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS containing AN777</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ONS without AN777</intervention_name>
    <description>2 servings a day</description>
    <arm_group_label>Control ONS</arm_group_label>
    <other_name>Commercially available ONS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ONS containing AN777</intervention_name>
    <description>2 servings a day</description>
    <arm_group_label>Investigational ONS</arm_group_label>
    <other_name>Investigational ONS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 60 to ≤ 79 years

          2. Body Mass Index (BMI) &gt;20 but ≤ 35 kg/m2.

          3. Short Physical Performance Battery (SPPB) score of &gt; 9 (fully functional with no
             mobility limitations).

          4. Triacylglyceride (TAG) level is ≤  250 mg/dl and LDL cholesterol is ≤ 150 mg/dl.

          5. Compliance with the various activity levels required for this study.

          6. Ankle brachial index within the normal range, between 1 and 1.4.

          7. Physical activity score within the 2008 Guidelines for Americans.

          8. Normal-good handgrip strength.

        Exclusion Criteria:

          1. Type I or Type II Diabetes Mellitus.

          2. Abnormal fasting blood glucose level.

          3. Major surgery, less than 6 weeks prior to enrollment in the study, or subject has
             planned elective surgery requiring 2 or more days of hospitalization.

          4. History of pressure ulcers.

          5. Stated history of Deep Vein Thrombosis (DVT), recent pulmonary embolism, carotid
             atherosclerosis, transient ischemic attack (TIA), or has a positive D-dimer test and
             lower extremity ultrasound at screening, or a known hypercoaguable condition, or
             other clotting or bleeding disorders, or is currently prescribed blood thinners.

          6. Varicose veins that would result in significant discomfort while wearing TED hose
             and/or SCD.

          7. Stated autoimmune disease or active malignant disease.

          8. Estimated glomerular filtration rate is &lt; 60ml/min/1.73m2.

          9. Current significantly impaired liver function or hepatic enzyme tests are ≥2.5 times
             normal limit.

         10. Significant cardiovascular event ≤ 6 months prior to screening visit; or stated
             history of congestive heart failure; or subject has evidence of cardiovascular
             disease assessed during the electrocardiogram (EKG) at screening.

         11. Hypo- or hyper-thyroidism, or other endocrinopathies associated with excessive
             androgen secretion.

         12. Refractory anemia with hemoglobin value &lt;11.0 g/dl.

         13. Chronic, contagious, infectious disease, such as active tuberculosis, hepatitis B or
             C, or HIV.

         14. Current infection (requiring prescription antimicrobial or antiviral medication, or
             hospitalization), or has received corticosteroid treatment (with the exception of
             inhaled or topical steroids) in the last 3 months.

         15. Currently being prescribed or has taken prescribed (high dose), but not over the
             counter, anti-inflammatory medication in the 6 weeks prior to screening.

         16. History of allergy to any of the ingredients in the study products.

         17. Currently taking statins and has a stated history of statin induced myopathy.

         18. Obstruction of the gastrointestinal tract precluding ingestion of the study product,
             inflammatory bowel disease, short bowel syndrome or other severe forms of
             gastrointestinal disease.

         19. Stated uncontrolled severe diarrhea, nausea or vomiting.

         20. Amputee.

         21. Actively pursuing weight loss or gain.

         22. Cannot refrain from taking medications/dietary supplements (all forms)/substances
             that could modulate metabolism or body weight.

         23. Cannot refrain from taking prescription level doses of eicosapentaenoic acid (EPA) ±
             docosahexaenoic acid (DHA) (≥1g/d), or vitamin D, (&gt;1,000IU/d) during the study.

         24. Cannot refrain from smoking or discontinue the use of nicotine (all forms including
             patches) or tobacco during the study.

         25. One or more metal implants.

         26. Currently diagnosis or a history of severe dementia or delirium, eating disorder,
             history of significant neurological or psychiatric disorder, alcoholism, substance
             abuse or other conditions that may interfere with study product consumption or
             compliance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen Kelly, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen DeLuca, MS, RD</last_name>
    <phone>614-624-5455</phone>
    <email>kristen.deluca@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences (UAMS)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-7199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Wolfe, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bret Goodpaster, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Translational Research in Aging &amp; Longevity</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77843-4253</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolaas EP Deutz, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
